Am­gen bar­rels in­to a $540M im­munother­a­py deal with Ad­vax­is

Am­gen has joined the im­munother­a­py part­ner­ing fren­zy. The Big Biotech is sign­ing up with the lit­tle biotech Ad­vax­is, col­lab­o­rat­ing on its tech­nol­o­gy us­ing bio­engi­neered bac­te­ria …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.